New York is currently home to 4494 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Transcranial Direct Current Stimulation for Post Treatment Lyme Disease
Recruiting
The primary purpose of this pilot study is to investigate a novel approach to the treatment of cognitive symptoms that persist despite prior antibiotic treatment for Lyme disease (Post treatment Lyme Disease or PTLD). Aim 1: The primary aim of this study is to assess whether the processing speed of individuals with PTLD can be enhanced by combining transcranial direct current stimulation (tDCS) with computer based cognitive training games. To achieve this aim, over a 4-week period, all individu... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/18/2025
Locations: Columbia University Department of Psychiatry, New York, New York
Conditions: Post-Treatment Lyme Disease
Ending the Epidemic Interventions in the Dental Setting - UH3
Recruiting
The purpose of this study is to use information technology (IT) to support the efficient delivery of HIV prevention and care best practices in the dental care setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York
Conditions: HIV-1-infection
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Recruiting
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and effective medications. A large National Institute of Health study called MILES showed that sirolimus (also known as Rapamycin) improved lung function in individuals with LAM. Since most individuals with LAM and impaired lung function are now on sirolimus, future studies... Read More
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
07/18/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Recruiting
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Cayuga Cancer Center, Ithaca, New York
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Recruiting
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Cayuga Cancer Center, Ithaca, New York
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Recruiting
The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/18/2025
Locations: NYU Langone Health, New York, New York
Conditions: Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Innovative Automated Insulin Delivery System for Type 2 Diabetes
Recruiting
The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Recruiting
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Memorial Sloan Kettering Cancer Center ( Site 0003), New York, New York
Conditions: Ovarian Cancer Recurrent
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Recruiting
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/18/2025
Locations: Davis Clinical, Bronx, New York
Conditions: Alcohol Use Disorder
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
Recruiting
The objective of this study is to evaluate the efficacy and/or safety of multiple therapies in patients with early-stage resectable NSCLC. Cohort B1 is a phase II cohort that will evaluate the safety, and efficacy of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection. Cohort B2 is a phase II cohort that will evaluate the efficacy and safety of perioperative alectinib in combination with chemotherapy in the neoad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Clinical Research Alliance, Westbury, New York
Conditions: Non-Small Cell Lung Cancer
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
Recruiting
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, many individuals do not un... Read More
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
07/18/2025
Locations: Montefiore Medical Center-Einstein Campus, Bronx, New York
Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: NYU Langone Hospital - Long Island ( Site 1230), Mineola, New York
Conditions: Gastrointestinal Cancer